SCHEMBL1007970

SCHEMBL1007970

O=S(=O)(CCCCCCCCCO)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 6/20 0.65
HDAC1 Q13547 3/20 0.60
HDAC2 Q92769 2/20 0.60
HDAC8 Q9BY41 2/20 0.60
HDAC3 O15379 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60
HDAC5 Q9UQL6 1/20 0.60
KEAP1 Q14145 1/20 0.53
NFE2L2 Q16236 1/20 0.53
HSD11B1 P28845 2/20 0.50
PSIP1 O75475 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
MMP3 P08254 2/20 0.45
MMP8 P22894 2/20 0.45
MMP13 P45452 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7295500 1.00 CA2 (0.65) CA2HDAC1HDAC2HDAC8HDAC3
SCHEMBL7298810 1.00 CA2 (0.65) CA2HDAC1HDAC2HDAC8HDAC3
SCHEMBL3917294 0.98 CA2 (0.67) CA2HDAC1HDAC2HDAC8HDAC3
SCHEMBL7207184 0.92 CA2 (0.66) CA2HDAC1HDAC2HDAC8HDAC3
SCHEMBL10626503 0.89 HDAC1 (0.65) CA2HDAC1HDAC2HDAC8HDAC3
SCHEMBL11309979 0.87 CA2 (0.81) CA2HDAC1HDAC2HDAC8HDAC3
SCHEMBL576918 0.87 KEAP1 (0.63) CA2HDAC1HDAC2HDAC8HDAC3
SCHEMBL10431476 0.85 CA2 (0.57) CA2HDAC1HDAC2HDAC8HDAC3
SCHEMBL15921376 0.84 HDAC1 (0.56) CA2HDAC1HDAC2HDAC8HDAC3
SCHEMBL2454945 0.83 CA2 (0.63) CA2HDAC1HDAC2HDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268606-B1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-08-06 EP disclosed
US-8344027-B2 4-dimethylaminobutyric acid derivatives HOFFMANN-LA ROCHE INC. (US) 2013-01-01 US disclosed
US-20120289554-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES ANDJELKOVIC MIRJANA (CH) 2012-11-15 US disclosed
EP-2268606-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
WO-2009132978-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO disclosed
US-20090270505-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270505-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES CPT1B, CPT1A, CPT2 CA2 1298/4885HDAC1 360/4885HDAC2 213/4885
US-20120289554-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES CPT1B, CPT1A, CPT2 CA2 1298/4885HDAC1 360/4885HDAC2 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.